Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-02-14 5:07 pm Purchase | 13G | Entrada Therapeutics, Inc. TRDA | Redmile Group LLC | 1,954,420 6.3% | 1,954,420 (New Position) | View |
| 2022-02-14 2:35 pm Purchase | 13G | Entrada Therapeutics, Inc. TRDA | PRICE T ROWE ASSOCIATES INC /MD/ | 2,020,637 6.4% | 2,020,637 (New Position) | View |
| 2022-02-14 06:19 am Purchase | 13G | Entrada Therapeutics, Inc. TRDA | ROCHE FINANCE LTD | 2,813,525 9% | 2,813,525 (New Position) | View |
| 2022-02-08 12:03 pm Purchase | 13G | Entrada Therapeutics, Inc. TRDA | MRL Ventures Fund LLC | 1,739,768 5.6% | 1,739,768 (New Position) | View |
| 2022-02-04 09:17 am Purchase | 13G | Entrada Therapeutics, Inc. TRDA | WELLINGTON MANAGEMENT GROUP LLP | 3,114,006 9.98% | 3,114,006 (New Position) | View |
| 2021-12-16 5:23 pm Unchanged | 13D | Entrada Therapeutics, Inc. TRDA | BAKER BROS. ADVISORS LP | 4,704,419 15.1% | 0 (Unchanged) | View |
| 2021-11-12 4:30 pm Purchase | 13D | Entrada Therapeutics, Inc. TRDA | 5AM Ventures V, L.P. | 4,409,687 14.8% | 4,409,687 (New Position) | View |
| 2021-11-12 4:07 pm Purchase | 13D | Entrada Therapeutics, Inc. TRDA | MPM BioVentures 2014 L.P. | 4,427,092 14.8% | 4,427,092 (New Position) | View |
| 2021-11-10 4:50 pm Purchase | 13G | Entrada Therapeutics, Inc. TRDA | BAKER BROS. ADVISORS LP | 4,704,419 15.1% | 4,704,419 (New Position) | View |